Proximie, Forbion, MicroTransponder
Matrix Requirements Receives EUR10M Investment From Lauxera Capital Partners
Lauxera Capital Partners acquired a majority stake in Matrix Requirements, a Berlin, Germany-based MedTech quality management software provider, for EUR10m.
The company intends to use the funds for active business development efforts alongside a product development roadmap.
Founded in 2014 by Wolfgang Huber (former VP R&D at Advanced Medical Diagnostics and co-founder of NeoMed Software) and Yves Berquin (former Program Manager at Advanced Medical Diagnostics and CTO at SleepOnWeb), Matrix Requirements has grown into a leader in the MedTech quality management system software space with two solutions: - MatrixALM, flexible software for managing medical device technical files with the goal of accelerating regulatory approvals (CE marking, FDA approval, etc.) and reducing non-compliance risk - MatrixQMS, a quality management system solution enabling MedTech companies to develop and maintain their own quality systems reflecting the specific needs of their products in compliance with ISO and FDA standards.
Matrix Requirements Receives EUR10M Investment From Lauxera Capital Partners - FinSMEs
Lauxera Capital Partners acquired a majority stake in Matrix Requirements, a Berlin, Germany-based MedTech quality management software provider, for EUR10m
Proximie Raises USD80M in Series C Funding
Proximie, a London, UK-based provider of a health technology platform, raised $80M in Series C funding.
The round was led by Advent Life Sciences with participation from Emerson Collective, Laurene Powell Jobs, SoftBank Vision Fund 2, British Patient Capital, Mubadala Investment Company, Minderoo Foundation, F-Prime Capital, Eight Roads, Questa Capital, Global Ventures, and Maverick Ventures.
The company, which has raised a total of $130m since inception, intends to use the funds to accelerate development of key products and services, build out its marketplace ecosystem and scale their Operating System of the OR – a centralized platform delivering connected surgical care.
Led by CEO Dr Nadine Hachach-Haram, Proximie provides a global health technology platform digitally connecting operating rooms (OR). Hospitals and surgical centers who leverage the technology will have access to preoperative data that can help inform patient care, real time collaborative tools to record, train, and deliver care, and postoperative content management tools to capture and distribute content to their colleagues.
Proximie Raises USD80M in Series C Funding - FinSMEs
Proximie, a London, UK-based provider of a health technology platform, raised $80M in Series C funding
Dren Bio Raises $65M in Series B Financing
Dren Bio, a Foster City, CA-based clinical-stage biopharmaceutical company, raised $65M in Series B funding.
The round was led by Aisling Capital and HBM Healthcare Investments, with participation from Pfizer, ArrowMark Partners, Revelation Partners, SR One, 8VC, Taiho Ventures, BVF Partners, Mission BioCapital and Alexandria Venture Investments, amongst others. In connection with the closing of the financing, Andrew Schiff, M.D., of Aisling Capital, and Chandra P. Leo, M.D., of HBM Partners, will join its Board of Directors.
Proceeds from the financing will enable the company to continue advancement of its broad internal pipeline comprised of multiple development candidates approaching the clinic.
Led by CEO Nenad Tomasevic, Dren Bio is a clinical-stage biopharmaceutical company focused on developing therapeutic antibodies for the treatment of cancer, autoimmune and other serious diseases. Its pipeline encompasses two distinct programs, the first focusing on the engineering of antibodies with enhanced antibody-dependent cellular cytotoxicity (“ADCC”) capabilities and the second revolving around its proprietary Targeted Myeloid Engager and Phagocytosis Platform. Its lead asset, DR-01, is designed to precisely eliminate a subset of immune cells which are the underlying cause of certain hematologic malignancies and well-defined autoimmune disorders, both of which will be evaluated using its current funding.
Dren Bio Raises $65M in Series B Financing - FinSMEs
Dren Bio, a Foster City, CA-based clinical-stage biopharmaceutical company, raised $65M in Series B funding
Sana Closes $60M Series B Growth Funding Round
Sana, an Austin, TX-based health care company that provides health benefits to small businesses, closed a $60 million Series B funding.
The round was co-led by original investors Trust Ventures and Gigafund with participation from existing investors American Family Ventures, mark vc, Breyer Capital, JAM Fund and Liquid 2.
The company, which has raised $107m to date, intends to use the funds to expand its team and member offerings, build new primary care health centers and accelerate growth into new markets.
Led by Will Young, co-founder and CEO, Sana provides small businesses with health plans and a care ecosystem of providers, direct primary care and more. Operating only in Texas in early 2020, the company is available in eight states and will continue its reach into new states during the coming months.
In January, the company opened Sana MD in Austin, Texas, its first primary care health center for members. In addition to in-person office visits, the company gives employees access to virtual care with providers specializing in primary care, pediatrics, maternity and mental health.
Sana Closes $60M Series B Growth Funding Round - FinSMEs
Sana, an Austin, TX-based health care company that provides health benefits to small businesses, closed a $60 million Series B funding
MicroTransponder Raises $53M in Series E Funding
MicroTransponder, an Austin, TX-based medical device company, raised $53M in Series E funding.
Backers included US Venture Partners, GPG Ventures, Exceller Hunt Ventures, Osage University Partners, Action Potential Venture Capital and The Vertical Group. As part of the investment, Casey Tansey of USVP and Bill Harrington of Osage University Partners will join the board of directors.
The company intends to use the funds to commercialize the Vivistim Paired VNS System and establish it as the recommended rehabilitation intervention for stroke survivors working to improve their quality of life through more hand and arm mobility.
Led by CEO Richard Foust, MicroTransponder is a global medical device company committed to developing research-based neuroscience solutions. The company focuses on restoring independence and dignity for people suffering from neurological conditions that impair sensory and motor function. MicroTransponder’s FDA-approved Vivistim Paired VNS System is a clinically proven medical technology designed to enhance daily living for people suffering from neurological conditions that impair sensory and motor function.
MicroTransponder Raises $53M in Series E Funding
MicroTransponder, an Austin, TX-based medical device company, raised $53M in Series E funding
Aidoc Raises $110M in Series D Funding
Aidoc, a Tel Aviv, Israel-based provider of healthcare AI solutions, raised $110m in Series D funding.
The round, which brought total funding to $250m, was co-led by global growth investors TCV and Alpha Intelligence Capital (AIC), with participation from AIC’s co-investor CDIB Capital.
The company intends to use the funds for the continued expansion of the Aidoc AI Care Platform.
Led by Elad Walach, CEO, Aidoc provides artificial intelligence healthcare solutions that empower physicians to expedite patient treatment and enhance operational capabilities. Its AI Care Platform offers health systems a singular platform solution that works with physicians to manage the entire patient lifecycle—from diagnostic aid, to consultation to suggested treatment paths to patient follow-up tools. In clinical studies, the Aidoc AI has proven to reduce turnaround time, shorten patient length of stay and improve patient outcomes.
Aidoc Raises $110M in Series D Funding
Aidoc, a Tel Aviv, Israel-based provider of healthcare AI solutions, raised $110m in Series D funding
Forbion Holds First Close of Forbion Growth Opportunities Fund II, at €470 Million
Forbion, a Naarden, The Netherlands, Munich, Germany-based life sciences venture capital firm, held the first €470 million (USD 500 million) close of its Forbion Growth Opportunities Fund I.
The fund has attracted several new institutional investors, including pension funds PME and PMT, the Ewing Marion Kauffman Foundation and Reggeborgh, who join returning investors Pantheon, Wealth Management Partners and Eli Lilly and Company.
Forbion expects to reach its €600 million hard cap, completing the raising of Forbion Growth Opportunities Fund II over the summer.
The second Forbion Growth Opportunities Fund will continue to invest in mostly European, later-stage biopharma companies, developing novel therapies for areas of high medical need. The fund will target this market segment with three proven strategies, providing:
- private growth capital for mature clinical development-stage assets,
- pre-IPO funding to companies pursuing a public listing in the near-term, and
- capital and hands-on capabilities to under-valued public companies.
In these financings, Forbion Growth Opportunities II aims to take leading positions with investment sizes of up to €70 million per deal. The team’s goal is to build a portfolio of 15 such investments in the most promising late-stage European life sciences companies.
Forbion manages well over EUR 2 billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drug development. Its current team consists of over 30 life sciences investment professionals that have built an impressive performance track record since the late nineties with investments in 87 companies.
